666 related articles for article (PubMed ID: 32760402)
1. Targeting Immunometabolism Mediated by CD73 Pathway in
Passarelli A; Aieta M; Sgambato A; Gridelli C
Front Immunol; 2020; 11():1479. PubMed ID: 32760402
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.
Ishii H; Azuma K; Kawahara A; Kinoshita T; Matsuo N; Naito Y; Tokito T; Yamada K; Akiba J; Hoshino T
Thorac Cancer; 2020 Apr; 11(4):950-955. PubMed ID: 32061060
[TBL] [Abstract][Full Text] [Related]
3. The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine.
Passarelli A; Tucci M; Mannavola F; Felici C; Silvestris F
Tumour Biol; 2019 Apr; 42(4):1010428319837138. PubMed ID: 30957676
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
Soo RA; Lim SM; Syn NL; Teng R; Soong R; Mok TSK; Cho BC
Lung Cancer; 2018 Jan; 115():12-20. PubMed ID: 29290252
[TBL] [Abstract][Full Text] [Related]
5. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
Front Immunol; 2021; 12():638763. PubMed ID: 34305884
[TBL] [Abstract][Full Text] [Related]
6. Landscape of adenosine pathway and immune checkpoint dual blockade in NSCLC: progress in basic research and clinical application.
Wang R; Liu Z; Wang T; Zhang J; Liu J; Zhou Q
Front Immunol; 2024; 15():1320244. PubMed ID: 38348050
[TBL] [Abstract][Full Text] [Related]
7. CXCR4 Inhibition Counteracts Immunosuppressive Properties of Metastatic NSCLC Stem Cells.
Fortunato O; Belisario DC; Compagno M; Giovinazzo F; Bracci C; Pastorino U; Horenstein A; Malavasi F; Ferracini R; Scala S; Sozzi G; Roz L; Roato I; Bertolini G
Front Immunol; 2020; 11():02168. PubMed ID: 33123122
[TBL] [Abstract][Full Text] [Related]
8. Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC.
Tu E; McGlinchey K; Wang J; Martin P; Ching SL; Floc'h N; Kurasawa J; Starrett JH; Lazdun Y; Wetzel L; Nuttall B; Ng FS; Coffman KT; Smith PD; Politi K; Cooper ZA; Streicher K
JCI Insight; 2022 Feb; 7(3):. PubMed ID: 35132961
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in advanced non-small-cell lung cancer with
Liu F; Yuan X; Jiang J; Chu Q
Immunotherapy; 2020 Nov; 12(16):1195-1207. PubMed ID: 32985295
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target.
Le X; Negrao MV; Reuben A; Federico L; Diao L; McGrail D; Nilsson M; Robichaux J; Munoz IG; Patel S; Elamin Y; Fan YH; Lee WC; Parra E; Solis Soto LM; Chen R; Li J; Karpinets T; Khairullah R; Kadara H; Behrens C; Sepesi B; Wang R; Zhu M; Wang L; Vaporciyan A; Roth J; Swisher S; Haymaker C; Zhang J; Wang J; Wong KK; Byers LA; Bernatchez C; Zhang J; Wistuba II; Gibbons DL; Akbay EA; Heymach JV
J Thorac Oncol; 2021 Apr; 16(4):583-600. PubMed ID: 33388477
[TBL] [Abstract][Full Text] [Related]
11. CD73 as a potential opportunity for cancer immunotherapy.
Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
[TBL] [Abstract][Full Text] [Related]
12. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
13. CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers.
Harvey JB; Phan LH; Villarreal OE; Bowser JL
Front Immunol; 2020; 11():508. PubMed ID: 32351498
[TBL] [Abstract][Full Text] [Related]
14. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.
Nagano T; Tachihara M; Nishimura Y
Curr Cancer Drug Targets; 2019; 19(8):595-630. PubMed ID: 30526458
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.
Zheng H; Zeltsman M; Zauderer MG; Eguchi T; Vaghjiani RG; Adusumilli PS
Immunotherapy; 2017 Sep; 9(11):913-927. PubMed ID: 29338609
[TBL] [Abstract][Full Text] [Related]
16. Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody-Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function.
Jin R; Liu L; Xing Y; Meng T; Ma L; Pei J; Cong Y; Zhang X; Ren Z; Wang X; Shen J; Yu K
Mol Cancer Ther; 2020 Nov; 19(11):2340-2352. PubMed ID: 32943546
[TBL] [Abstract][Full Text] [Related]
17. Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways.
Giatromanolaki A; Kouroupi M; Pouliliou S; Mitrakas A; Hasan F; Pappa A; Koukourakis MI
Life Sci; 2020 Oct; 259():118389. PubMed ID: 32898522
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for non-small-cell lung cancer.
Thomas A; Jakopovic M
Expert Opin Biol Ther; 2014 Aug; 14(8):1061-4. PubMed ID: 24878420
[TBL] [Abstract][Full Text] [Related]
19. Identification of Clonal Neoantigens Derived From Driver Mutations in an
Wu D; Liu Y; Li X; Liu Y; Yang Q; Liu Y; Wu J; Tian C; Zeng Y; Zhao Z; Xiao Y; Gu F; Zhang K; Hu Y; Liu L
Front Immunol; 2020; 11():1366. PubMed ID: 32793190
[TBL] [Abstract][Full Text] [Related]
20. EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment.
Madeddu C; Donisi C; Liscia N; Lai E; Scartozzi M; Macciò A
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
